The stock of Dyne Therapeutics Inc (DYN) has gone down by -5.25% for the week, with a -11.98% drop in the past month and a -9.74% drop in the past quarter. The volatility ratio for the week is 3.71%, and the volatility levels for the past 30 days are 6.37% for DYN. The simple moving average for the last 20 days is -18.82% for DYN stock, with a simple moving average of -48.37% for the last 200 days.
Is It Worth Investing in Dyne Therapeutics Inc (NASDAQ: DYN) Right Now?
The stock has a 36-month beta value of 1.14. Opinions on the stock are mixed, with 8 analysts rating it as a “buy,” 7 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for DYN is 85.23M, and at present, short sellers hold a 29.95% of that float. On June 25, 2025, the average trading volume of DYN was 2.70M shares.
DYN) stock’s latest price update
Dyne Therapeutics Inc (NASDAQ: DYN) has seen a decline in its stock price by -3.20 in relation to its previous close of 10.63. However, the company has experienced a -5.25% decline in its stock price over the last five trading sessions. prnewswire.com reported 2025-06-24 that LOS ANGELES, June 24, 2025 /PRNewswire/ — The DJS Law Group announces that it is investigating claims on behalf of investors of Dyne Therapeutics (“Dyne” or “the Company”) (NASDAQ: DYN) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors.
Analysts’ Opinion of DYN
Many brokerage firms have already submitted their reports for DYN stocks, with Bernstein repeating the rating for DYN by listing it as a “Mkt Perform.” The predicted price for DYN in the upcoming period, according to Bernstein is $13 based on the research report published on June 24, 2025 of the current year 2025.
Raymond James, on the other hand, stated in their research note that they expect to see DYN reach a price target of $37. The rating they have provided for DYN stocks is “Outperform” according to the report published on June 11th, 2025.
Oppenheimer gave a rating of “Outperform” to DYN, setting the target price at $34 in the report published on June 02nd of the current year.
DYN Trading at -11.38% from the 50-Day Moving Average
After a stumble in the market that brought DYN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -78.31% of loss for the given period.
Stock Fundamentals for DYN
The total capital return value is set at -0.58. Equity return is now at value -64.01, with -59.05 for asset returns.
Based on Dyne Therapeutics Inc (DYN), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -13.7.
Currently, EBITDA for the company is -315.18 million with net debt to EBITDA at 1.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 20.35.
Conclusion
To sum up, Dyne Therapeutics Inc (DYN) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
